+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Paraneoplastic neurological syndromes



Paraneoplastic neurological syndromes



Current Opinion in Neurology 15(6): 685-690



This review discusses recent advances and current controversies in the aetiology, investigation and management of paraneoplastic neurological syndromes. Antibody studies continue to define potential target autoantigens in paraneoplastic neurological syndromes and although pathogenic activity has been demonstrated for anti-glutamate receptor antibodies identified in a subset of patients with cerebellar ataxia, a role for paraneoplastic antibodies in the development of neuronal dysfunction has not been established in the majority of cases. As a result, attention has turned towards clarifying the role of adaptive cellular immunity in the pathogenesis of paraneoplastic neurological syndromes and several studies have defined expanded populations of cytotoxic T lymphocytes specific for epitopes derived from neuronal antigens in patients with paraneoplastic neurological syndromes. In vitro studies demonstrate the potential for antigen-specific cytotoxic T lymphocytes to restrict tumour growth and metastasis, but further investigation is needed to identify the mechanisms by which cytotoxic T lymphocytes could induce neuronal death. Clinical studies have demonstrated that effective tumour treatment can in some instances lead to improvement or stabilization of neurological symptoms. This is an encouraging observation since increased numbers of diagnostic paraneoplastic antibodies can now be reliably tested for and the use of [18F] fluoro-2-deoxyglucose positron emission tomography can facilitate earlier tumour diagnosis in patients presenting with paraneoplastic neurological syndromes. Advances in the clinical management of patients with paraneoplastic neurological syndromes have occurred despite the fact that in most cases the immune effector mechanisms that lead to the development of neurological dysfunction remain to be characterized.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 046916526

Download citation: RISBibTeXText

PMID: 12447106

DOI: 10.1097/01.wco.0000044764.39452.64


Related references

A nationwide survey on paraneoplastic neurological syndromes. Project group on paraneoplastic neurological syndromes, Neuroimmunological Disease Research Committee, the Ministry of Health and Welfare, Japan. Rinsho Shinkeigaku 37(2): 93-98, 1997

Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 3: Neurological paraneoplastic syndromes, involving the central nervous system. Lung Cancer 106: 83-92, 2017

Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature Part 4: Neurological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles. Lung Cancer 111: 150-163, 2017

Accuracy of FDG-PET/CT and paraneoplastic antibodies in diagnosing cancer in paraneoplastic neurological syndromes. Revista Espanola de Medicina Nuclear E Imagen Molecular 35(1): 17-21, 2016

Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature. Breast Cancer Research and Treatment 105(2): 133-138, 2007

Paraneoplastic neurological syndromes. "Transverse myelitis or paraneoplastic myelomalacia". Il Fracastoro 61(1): 47-54, 1968

Recombinant immunoblot for assessment of intrathecally synthesised paraneoplastic antineuronal antibodies in cerebrospinal fluid from patients with paraneoplastic neurological syndromes. Clinical Chemistry and Laboratory Medicine 46(12): 1793-1795, 2008

Paraneoplastic neurological syndromes: severe neurological symptoms resulting from relatively benign or occult tumours-two case reports. Case Reports in Oncological Medicine 2013: 458378, 2013

Paraneoplastic neurological syndromes: paraneoplastic or neurological?. Archives of Neurology 56(2): 151-152, 1999

Neurological Paraneoplastic Syndromes. The Neuroscientist 4(6): 443-453, 1998

Paraneoplastic neurological syndromes. Tidsskrift for den Norske Laegeforening 129(6): 524-528, 2009

Neurological paraneoplastic syndromes. Journal of Clinical Pathology 50(12): 975-980, 1997

Neurological paraneoplastic syndromes. Cancer Investigation 6(1): 67-82, 1988

Paraneoplastic neurological syndromes. Clinical and Experimental Immunology 175(3): 336-348, 2014

Paraneoplastic neurological syndromes. Orphanet Journal of Rare Diseases 2: 22, 2007